Does symbiotic supplementation which contains Bacillus Coagulans Lactobacillus rhamnosus, Lactobacillus acidophilus and fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial.

2021-06-02
Archives of physiology and biochemistry 129(6)
- Aynaz Velayati
- Iman Kareem
- Meghdad Sedaghat
- Golbon Sohrab
- Omid Nikpayam
- Mehdi Hedayati
- Khadijeh Abhari
- Ehsan Hejazi

PubMed: 34077686
DOI: 10.1080/13813455.2021.1928225

Study Design

Type: Randomized Controlled Trial (RCT)
Sample size: n = 50
Population: 50 patients with type-2 diabetes
Methods: randomly assigned to the symbiotic or placebo groups to receive one sachet daily for 12 weeks
Duration: 12 weeks

This study aimed to determine the effect of Bacillus Coagulans symbiotic supplementation on metabolic factors and inflammation in patients with type-2 diabetes. In this clinical trial, 50 patients with type-2 diabetes were randomly assigned to the symbiotic (containing Bacillus Coagulans + Lactobacillus rhamnosus + Lactobacillus acidophilus and fructooligosaccharide) or placebo groups to receive one sachet daily for 12 weeks. Glycaemic Index, lipid profile, and hs-CRP were measured at the beginning and end of the study. Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group. So, the current study indicated that Bacillus Coagulans symbiotic supplementation could improve metabolic factors and inflammation in patients with type-2 diabetes.

Research Insights

Bacillus coagulans→Improved Insulin Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Bacillus coagulans→Improved Insulin Sensitivity
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Moderate
Dose
one sachet daily for 12 weeks
Bacillus coagulans→Reduced Fasting Blood Glucose Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Moderate
Dose
one sachet daily for 12 weeks
Bacillus coagulans→Reduced High-Sensitivity C-Reactive Protein Level
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Bacillus coagulans→Reduced Insulin Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Lactobacillus acidophilus→Improved Insulin Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Lactobacillus acidophilus→Improved Insulin Sensitivity
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Moderate
Dose
one sachet daily for 12 weeks
Lactobacillus acidophilus→Reduced Fasting Blood Glucose Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Moderate
Dose
one sachet daily for 12 weeks
Lactobacillus acidophilus→Reduced High-Sensitivity C-Reactive Protein Level
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Lactobacillus acidophilus→Reduced Insulin Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Lactobacillus rhamnosus→Improved Insulin Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Lactobacillus rhamnosus→Improved Insulin Sensitivity
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Moderate
Dose
one sachet daily for 12 weeks
Lactobacillus rhamnosus→Reduced Fasting Blood Glucose Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Moderate
Dose
one sachet daily for 12 weeks
Lactobacillus rhamnosus→Reduced High-Sensitivity C-Reactive Protein Level
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks
Lactobacillus rhamnosus→Reduced Insulin Levels
Analysis of covariance demonstrated that fasting blood glucose (FBG), insulin, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), β-cell function (HOMA-β) (p <.05) and hs-CRP (p <.05) significantly declined in the treatment group compared with the placebo group.
Effect
Beneficial
Effect size
Small
Dose
one sachet daily for 12 weeks